drug
epcoritamab
Marketedupdated 6mo agoby Genmab AS
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
DLBCL
all catalysts(5)
approval · 5
May 19, 2023
approval
EPKINLY (EPCORITAMAB-BYSP) — FDA approval
epcoritamab
→
Jun 26, 2024
approval
EPKINLY (EPCORITAMAB-BYSP) — FDA approval
epcoritamab
→
Sep 11, 2025
approval
EPKINLY (EPCORITAMAB-BYSP) — FDA approval
epcoritamab
→
Nov 18, 2025
approval
EPKINLY (EPCORITAMAB-BYSP) — FDA approval
epcoritamab
→
Mar 27, 2026
approval
EPKINLY (EPCORITAMAB-BYSP) — FDA approval
epcoritamab
→
Trials studying epcoritamab
- phase2A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- phase2Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- phase2Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
- phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- phase2Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
- phase1Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
- phase2Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
- phase2First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
News(10)
- Genmab soars to record highs after cancer drug succeeds in key trialThe drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.biopharma_dive · 19d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 20d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 20d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 22d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 29d ago
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.biopharma_dive · 1mo ago
- AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…biospace · 1mo ago
- AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to PolivyAbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market showdown with Roche’s antibody-dru…endpoints · 1mo ago
- AbbVie and Genmab's latest win brings Epkinly closer to label expansionAbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B cell lymphoma.…endpoints · 4mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that